A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue in patients with high-grade glioma (Alliance A221101).
Article
Porter, Alyx B, Liu, Heshan, Kohli, Sadhna et al. (2020). A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue in patients with high-grade glioma (Alliance A221101).
. JOURNAL OF CLINICAL ONCOLOGY, 38(15_suppl), 12007-12007. 10.1200/jco.2020.38.15_suppl.12007
Porter, Alyx B, Liu, Heshan, Kohli, Sadhna et al. (2020). A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue in patients with high-grade glioma (Alliance A221101).
. JOURNAL OF CLINICAL ONCOLOGY, 38(15_suppl), 12007-12007. 10.1200/jco.2020.38.15_suppl.12007
Porter, Alyx B; Liu, Heshan; Kohli, Sadhna; Cerhan, Jane H; Sloan, Jeff A; McMurray, Ryan; Le-Rademacher, Jennifer; Loprinzi, Charles L; Villano, John L; Kizilbash, Sani Haider; Mehta, Minesh P; Jaeckle, Kurt A; Brown, Paul D